{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:22Z","timestamp":1794013282156,"version":"4.8.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.xkme.2022.100483","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T13:21:56Z","timestamp":1653052916000},"page":"100483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)"],"prefix":"10.1016","volume":"4","author":[{"given":"Cara","family":"East","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Rahimighazikalayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodoro","family":"Bottiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2022.100483_bib2","author":"Arora"},{"issue":"9","key":"10.1016\/j.xkme.2022.100483_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/ncpneph0570","article-title":"Racial and survival paradoxes in chronic kidney disease","volume":"3","author":"Kalantar-Zadeh","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2022.100483_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2022.100483_bib5","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.kint.2015.12.033","article-title":"Long-term effects following 4 years of randomized treatment\u00a0with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis","volume":"89","author":"Krane","year":"2016","journal-title":"Kidney Int"},{"issue":"14","key":"10.1016\/j.xkme.2022.100483_bib6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing\u00a0hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N\u00a0Eng J Med"},{"issue":"9784","key":"10.1016\/j.xkme.2022.100483_bib7","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.xkme.2022.100483_bib8","article-title":"Statins and all-cause mortality in patients undergoing hemodialysis","volume":"9","author":"Jung","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.xkme.2022.100483_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.xkme.2022.100483_bib10","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xkme.2022.100483_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.amjcard.2020.04.052","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 inhibitors on plasma ceramide levels","volume":"128","author":"Ye","year":"2020","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.xkme.2022.100483_bib12","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00125-020-05201-9","article-title":"Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes","volume":"63","author":"Pongrac Barlovic","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.xkme.2022.100483_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0Royal Statistical Soc"},{"issue":"7","key":"10.1016\/j.xkme.2022.100483_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2215\/CJN.10441015","article-title":"Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD","volume":"11","author":"Sun","year":"2016","journal-title":"Clin J Am Soc Nephol"},{"key":"10.1016\/j.xkme.2022.100483_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cca.2020.10.005","article-title":"Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors","volume":"511","author":"Meeusen","year":"2020","journal-title":"Clin Chim Acta"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059522000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059522000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:23:20Z","timestamp":1762910600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059522000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2590059522000991"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2022.100483","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2022.100483","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100483"}}